Hycamtin

Rhabdomyosarcoma, Lymphoma, Malignant neoplasm of ovary + 5 more
Treatment
3 FDA approvals
20 Active Studies for Hycamtin

What is Hycamtin

TopotecanThe Generic name of this drug
Treatment SummaryAn antineoplastic agent used to treat ovarian cancer. It stops the growth of cancer cells by blocking the enzymes that help them replicate and divide.
Hycamtinis the brand name
image of different drug pills on a surface
Hycamtin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hycamtin
Topotecan
1996
29

Approved as Treatment by the FDA

Topotecan, also known as Hycamtin, is approved by the FDA for 3 uses such as Malignant neoplasm of ovary and refractory, metastatic Ovarian cancer .
Malignant neoplasm of ovary
refractory, metastatic Ovarian cancer
Metastatic Cervical Cancer
Used to treat Metastatic Cervical Cancer in combination with Cisplatin

Effectiveness

How Hycamtin Affects PatientsTopotecan is a medication derived from a tree called Camptotheca acuminata and works by stopping cancer cells from growing. It does this by blocking the activity of an enzyme (DNA topoisomerase) that helps the cells replicate and survive. As this medication affects the growth of both healthy and cancer cells, other side effects may occur. Topotecan is not a prodrug and can be taken in its active form.
How Hycamtin works in the bodyTopotecan works by preventing the repair of single strand breaks in DNA. It does this by blocking the enzyme that would normally repair the breaks. This enzyme is known as topoisomerase I. When the breaks cannot be repaired, they form double strand breaks which are too severe for the cell to repair, leading to cell death. Topotecan works by attaching itself to the enzyme and the DNA, stopping the repair process.

When to interrupt dosage

The suggested measure of Hycamtin is contingent upon the identified affliction, including Malignant neoplasm of ovary, Lymphoma and metastatic Rhabdomyosarcoma. The magnitude of dosage is contingent upon the system of delivery featured in the table beneath.
Condition
Dosage
Administration
Lymphoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
refractory CNS malignancy
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Malignant Neoplasms
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Malignant neoplasm of ovary
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Rhabdomyosarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Sarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Acute Myeloid Leukemia
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Neuroblastoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Hycamtin.
Common Hycamtin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept.
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Topotecan.
Abetimus
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abetimus.
Hycamtin Toxicity & Overdose RiskTaking too much of this medication may cause a decrease in healthy blood cells produced in the bone marrow.
image of a doctor in a lab doing drug, clinical research

Hycamtin Novel Uses: Which Conditions Have a Clinical Trial Featuring Hycamtin?

336 clinical trials are currently underway to investigate the potential of Hycamtin for treating Malignant Neoplasm of Ovary, Malignant Neoplasms and Metastatic Rhabdomyosarcoma.
Condition
Clinical Trials
Trial Phases
Acute Myeloid Leukemia
274 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Neuroblastoma
0 Actively Recruiting
Malignant neoplasm of ovary
0 Actively Recruiting
Lymphoma
0 Actively Recruiting
Rhabdomyosarcoma
0 Actively Recruiting
refractory CNS malignancy
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Sarcoma
1 Actively Recruiting
Phase 2

Patient Q&A Section about hycamtin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Hycamtin?

"At one year, 33 percent of patients treated with oral topotecan were still alive, compared to 29 percent of those treated with IV topotecan. Two years after treatment, 12 percent of those who had received oral topotecan were alive, compared to 7 percent of those treated with IV topotecan."

Answered by AI

What is topotecan used for?

"This medicine is used to treat metastatic cancer of the ovaries and small cell lung cancer."

Answered by AI

What is Hycamtin used for?

"This medication is used to treat small cell lung cancer. Its mechanism of action is either killing cancer cells or slowing their growth."

Answered by AI

Who manufactures Hycamtin?

"Hycamtin is a drug manufactured by GlaxoSmithKline that garnered $203.5 million in sales in 2003. It is approved by the FDA to treat ovarian cancers after failure of first-line chemotherapy, and it is the only drug approved by the FDA to treat small-cell lung cancers after failure of first-line chemotherapy."

Answered by AI

Clinical Trials for Hycamtin

Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.
Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.
Have you considered Hycamtin clinical trials? We made a collection of clinical trials featuring Hycamtin, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top